Access provided by
London Metropolitan University
The National Institute for Health and Care Excellence (NICE) has recommended the drug dinutuximab beta for the treatment of high-risk neuroblastoma – a rare type of cancer that mainly affects children and young people.
Cancer Nursing Practice. 17, 5, 10-10. doi: 10.7748/cnp.17.5.10.s8
Alternatively, you can purchase access to this article for the next seven days. Buy now
Are you a student? Our student subscription has content especially for you.
Find out more